

Analysis of the duration of combination therapy that is necessary for hepatitis C (HCV) genotype 1 eradication

Submission date
30/09/2004

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
30/09/2004

Overall study status
Completed

☐ Statistical analysis plan

☐ Results

Last Edited
18/07/2016

Condition category
Infections and Infestations

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr N V Naoumov

Contact details

General Medicine (Hepatology)
Institute of Hepatology
University College London
69-75 Chenies Mews
London
United Kingdom
WC1E 6HX
+44 (0)20 7388 2013
n.naoumov@ucl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0263132921

Study information

Scientific Title

Analysis of the duration of combination therapy that is necessary for hepatitis C (HCV) genotype 1 eradication

Study objectives

What is the duration of combination therapy required in order to produce a sustained viral clearance in hepatitis C infected patients

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Infections and Infestations: Hepatitis C

Interventions

Randomised Controlled Trial

1. Chemotherapy 1
2. Chemotherapy 2

Intervention Type

Drug

Phase

Not Applicable

Primary outcome measure

Viral clearance

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/10/2003

Completion date

01/10/2005

Eligibility

Key inclusion criteria

50 patients from Hepatology

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

50

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/10/2003

Date of final enrolment

01/10/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

University College London
London
United Kingdom
WC1E 6HX

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University College London Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration